Contact

Welcome to Proteomics​

Control, prevention, and treatment of infection have become one of the greatest challenges facing healthcare systems worldwide. The rise of so-called superbugs has fundamentally changed how infections behave—and how difficult they are to treat.

Research and pipeline products are currently in the early stages of development and have not been cleared or approved by the U.S. Food and Drug Administration (FDA). These products are not in clinical trials and are not available for sale or commercial distribution in the United States. The safety and effectiveness have not yet been established. Statements regarding its potential use are based on in vitro or preclinical data and are for informational purposes only.

Weaponizing Nature’s Own Defense

A superbug is a microorganism—most often a bacterium—that has developed resistance to one or more antibiotics, making infections increasingly difficult, and in some cases impossible, to treat using standard therapies.

Normal Bacteria

Antibiotics work effectively. Bacteria die when exposed to treatment.

Superbug

Antibiotics fail. Bacteria survive and continue multiplying despite treatment.

Lead Drug Candidate

Weaponized Protein Technology

Over the last decade, Spectrum Antimicrobials has developed patented molecules and processes to convert naturally occurring proteins in the human body into therapeutic weapons with superior efficacy.

Key Advantages for the target drug candidate (SPC-02):

  • 4,000X greater efficacy than conventional HOCl
  • Maintains activity in high-protein environments
  • Penetrates biofilms that protect bacteria
  • 100% biocompatible with human tissues
  • Zero risk of resistance development
4000 X

Greater Efficacy

100 %

Biocompatible

< 1%

Resistant Risk​

Disclosure

DISCLOSURE for R&D Products
Research and pipeline products are currently in the early stages of development and have not been cleared or approved by the U.S. Food and Drug Administration (FDA). These products are not in clinical trials and are not available for sale or commercial distribution in the United States. The safety and effectiveness have not yet been established. Statements regarding its potential use are based on in vitro or preclinical data and are for informational purposes only. 

This page provides scientific and clinical information related to the development of innovative chemistries and proteomic approaches designed by Spectrum Antimicrobials team to advance new medical product and drugs for better control, prevention, and treatment of infection. Our scientific mission is to reduce reliance on ineffective or overused antibiotics and antimicrobials through evidence-based innovation.

Information presented on this site is solely provided for informational purposes and cannot be used to support any commercial use of our products in any parts pf the word. All products are cleared and/or approved on a country-by-country basis in accordance with applicable local regulatory requirements. Any use outside of approved indications or labeling is strictly prohibited.

No commercial products may be ordered, and no promotional materials for any commercial product are offered through this website worldwide. For product inquiries or purchasing information, please contact sales@spectrumantimicrobials.com or visit our designated e-commerce website (xx@.com).

I CONSENT